Data compiled by Redley Lamar · ChainSifter Intelligence
9Suppliers
12Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Nurix Therapeutics, Inc. (NRIX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
25Total relationships
5Distinct source URLs
11High confidence
0.794Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Nurix Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
PIPER-SANDLER-CO
PIPER-SANDLER-CO
90%
the Company may offer and sell through Piper Sandler, as sales agent, $413.65 million of shares of the Company’s common stock
Reciprocal relationship from CCCC graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from CCCC graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from CCCC g…
Reciprocal relationship from CRIS graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from CRIS graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from CRIS g…
g Administration (FDA), the European Medicines Agency (EMA) or other regulatory authorities to perform trials in addition to those we currently expect, or if there are any delays in establishing appr…
Reciprocal relationship from GILD graph: Reciprocal relationship from NRIX graph: g Administration (FDA), the European Medicines Agency (EMA) or other regulatory authorities to perform trials in addi…
Reciprocal relationship from GLUE graph: current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of t…
Reciprocal relationship from KYMR graph: current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of t…
SNYNF
Sanofi
72%
, have an exercise price of $0.001 and may be exercised at any time after the date of issuance. A holder of the pre-funded warrants may not exercise the warrant if the holder, together with its affil…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from NRIX graph: , have an exercise price of $0.00…
Nurix Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
F-HOFFMANN-LA-ROCHE-LTD
F-HOFFMANN-LA-ROCHE-LTD
92%
Nurix will grant Roche an exclusive worldwide license, including with respect to Nurix and its affiliates, under certain Nurix intellectual property rights
GENENTECH-INC
GENENTECH-INC
92%
Nurix will grant Roche an exclusive worldwide license, including with respect to Nurix and its affiliates, under certain Nurix intellectual property rights
GILEAD
GILEAD
92%
Under the Gilead Agreement, Gilead has the option to license drug candidates directed to up to five targets resulting from the collaboration and is responsible for the clinical development and commer…
SANOFI
SANOFI
90%
In December 2019, we entered into a strategic collaboration with Genzyme Corporation, a subsidiary of Sanofi, which became effective in January 2020
In our partnership with Pfizer, which was announced in September 2023 under an agreement with Seagen, Inc., we have achieved two preclinical milestones to date, qualifying for $10.0 million in milest…
Reciprocal relationship from PFE graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from PFE graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from PFE grap…
g Administration (FDA), the European Medicines Agency (EMA) or other regulatory authorities to perform trials in addition to those we currently expect, or if there are any delays in establishing appr…
Reciprocal relationship from GILD graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from GILD g…
Reciprocal relationship from KYMR graph: hese manufacturers on a purchase order basis and do not have long-term supply arrangements in place. Should any of these manufacturers become unavailable to u…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from NRIX graph: , have an exercise price of $0.001 and may be exercised at any time after the date of issuance. A holder of the pre-…
SNYNF
Sanofi
72%
, have an exercise price of $0.001 and may be exercised at any time after the date of issuance. A holder of the pre-funded warrants may not exercise the warrant if the holder, together with its affil…
Reciprocal relationship from SI graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from SI graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from SI graph: …
Nurix Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
NRIX-DEBT
Debt stack $58.7M
90%
Market cache reports total debt of $58.7M.
NRIX-DEBT-11362
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-11-30.
NRIX-DEBT-11361
Warrants outstanding: 94759000
90%
xbrl warrant detail from xbrl 2022-11-30.
Nurix Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Nurix Therapeutics, Inc..
Nurix Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
NRIX-OWNER-MORGAN-STANLEY
MORGAN STANLEY
90%
13F overlay lists MORGAN STANLEY as top holder; 198 tracked holders.
Nurix Therapeutics, Inc. Extended Supply Chain Network
